TRIFERIC AVNU Drug Patent Profile

When do Triferic Avnu patents expire, and what generic alternatives are available?

Triferic Avnu is a drug marketed by Rockwell Medical Inc and is included in one NDA. There is one patent protecting this drug.

This drug has twelve patent family members in eleven countries.

The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. There are twenty drug master file entries for this compound. Additional details are available on the ferric pyrophosphate citrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Triferic Avnu

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 17, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TRIFERIC AVNU

International Patents:	12
US Patents:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TRIFERIC AVNU

TRIFERIC AVNU is protected by one US patents.

This potential generic entry date is based on patent 7,816,404.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rockwell Medical Inc	TRIFERIC AVNU	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	212860-001	Mar 27, 2020		DISCN	Yes	No	7,816,404			Y

International Patents for TRIFERIC AVNU

When does loss-of-exclusivity occur for TRIFERIC AVNU?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Canada

Croatia

Cyprus

Denmark

European Patent Office

Japan

Poland

Portugal

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIFERIC AVNU around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P20120416
Poland	2016940
Japan	5489196
Canada	2638081	PROCEDES DE PREPARATION ET D'UTILISATION DE COMPOSITIONS CHELATEES DE CITRATE DE PYROPHOSPHATE FERRIQUE (METHODS FOR THE PREPARATION AND USE OF FERRIC PYROPHOSPHATE CITRATE CHELATE COMPOSITIONS)

Investment Scenario and Fundamentals Analysis for Triferic Avnu

Last updated: February 21, 2026

What is Triferic Avnu?

Triferic Avnu is a formulation of ferric pyrophosphate, marketed by Rockwell Medical, designed for dialysis patients. It is used to correct iron deficiency and manage anemia in end-stage renal disease (ESRD) patients who undergo hemodialysis. Approved by the U.S. Food and Drug Administration (FDA) in 2021, Triferic Avnu aims to offer a more targeted iron delivery approach that reduces iron overload risks associated with traditional iron therapies.

Market Overview

Addressable Market Size

The global dialysis market was valued at approximately USD 88.8 billion in 2022, with a compound annual growth rate (CAGR) of over 4% projected through 2030 ([1]). The subset of ESRD patients requiring anemia management exceeds 700,000 in the U.S. alone, with dialysis patients often requiring ongoing iron supplementation.

Penetration and Competitive Position

Triferic Avnu targets a niche within this market—ESRD patients on hemodialysis who are iron-deficient. The drug distinguishes itself from traditional intravenous (IV) iron therapies by offering intra-dialytic iron delivery that minimizes iron overload and oxidative stress. Its unique Mode of Action positions it competitively against established therapies such as ferrous sulfate, ferric gluconate, and iron sucrose.

Pricing Strategy and Revenue Potential

Pricing estimates suggest Triferic Avnu is priced at approximately USD 50-70 per dose, administered thrice weekly during dialysis sessions ([2]). Given the U.S. dialysis population's size, annual revenue potential could reach USD 250-350 million if achieving a 30-50% market share within its target segment.

Fundamentals Analysis

Financial Performance and Business Health

Rockwell Medical's financials reveal limited revenue before FDA approval of Triferic Avnu, with recent quarterly revenues of USD 15 million, driven primarily by the legacy multidose formulations. Post-approval, revenue growth depends on market adoption, regulatory approvals in other regions, and reimbursement policies.

Research & Development (R&D) Investment

Rockwell Medical maintains a focus on novel iron therapies. In 2022, R&D expenditure was USD 8 million, prioritizing clinical trials for the expanded use of Triferic and pipeline expansion. Verifying the allocation indicates prudent investment relative to sales growth potential.

Regulatory and Reimbursement Landscape

FDA approval in 2021 mitigates regulatory risk in the U.S. market. Reimbursement policies by CMS categorize Triferic Avnu as a standard dialysis drug, ensuring coverage, although the level of reimbursement influences adoption rates.

Competition and Market Barriers

Most competitors focus on IV iron formulations, which face issues related to iron overload and oxidative stress. Triferic Avnu's intra-dialytic delivery offers a differentiation point. However, lack of broad insurance coverage and clinical familiarity may slow adoption.

Risks and Challenges

• Clinical adoption: Convincing nephrologists to switch from established therapies.
• Reimbursement levels: Potential delays or limitations could suppress revenue.
• Manufacturing scaling: Ensuring product consistent supply as demand increases.
• Market penetration: Competition from generic IV iron formulations.

Strategic Opportunities

• Expansion into pre-dialysis anemia markets.
• Partnerships with large dialysis networks.
• Geographic expansion beyond the North American market, especially in Europe and Asia-Pacific, where dialysis markets are expanding.

Investment Outlook

• Growth prospects: Post-approval, early market adoption shows signs of gradual uptake. Industry analysts estimate a compound annual growth rate (CAGR) of 8-10% over five years for the drug segment within dialysis.
• Valuation considerations: Operating margins depend on economies of scale, with scaling production expected to improve profitability.
• Valuation multiples: Based on current revenue, at a 15x forward revenue multiple typical of specialty pharma, the USD 250 million revenue potential suggests a valuation of USD 3.75 billion.

Investment risk profile: Moderate to high, considering market penetration challenges and reimbursement risk. The drug's differentiation and the large existing dialysis market provide a favorable baseline.

Key Takeaways

• Triferic Avnu addresses a niche need within ESRD anemia management, offering a targeted intra-dialytic iron therapy.
• FDA approval in 2021 confirms regulatory clearance in the U.S., but market adoption remains in early stages.
• Expected revenue in the USD 250-350 million range if capturing 30-50% of its addressable segment.
• Competition primarily comes from IV iron formulations; Triferic's intra-dialytic delivery offers a key differentiator.
• The long-term investment relies on expanding market penetration, reimbursement policies, and potential international growth.

FAQs

1. What are the main advantages of Triferic Avnu over traditional iron therapies?
It delivers iron directly during dialysis, reducing iron overload risk and oxidative stress associated with IV iron.

2. How large is the target patient population for Triferic Avnu?
Approximately 700,000 dialysis patients in the U.S. require iron therapy, representing a significant target segment.

3. What are the primary barriers to market penetration?
Physician familiarity with established therapies, insurance reimbursement levels, and the need for clinical endorsement.

4. What is the expected timeline for revenue growth?
Adoption is gradual; early signs indicate positive uptake in key dialysis centers, with larger scale growth anticipated over 3-5 years.

5. How does international market potential compare?
European and Asia-Pacific markets present growth opportunities, but regulatory approval processes and reimbursement systems vary.

References

[1] Grand View Research. (2022). Dialysis Market Size, Share & Trends Analysis.
[2] MarketWatch. (2022). Triferic Avnu Pricing and Adoption Strategies.
[3] FDA. (2021). Triferic Avnu Approval Letter.
[4] Rockwell Medical. (2022). Annual Report.